香港股市 已收市

Fresenius Medical Care AG (FMCQF)

OTC Markets OTCPK - OTC Markets OTCPK 延遲價格。貨幣為 USD。
加入追蹤清單
47.05+2.71 (+6.12%)
市場開市。 截至 09:37AM EDT。

Fresenius Medical Care AG

Else-KrOener-Strasse 1
Bad Homburg 61352
Germany
49 6172 609 0
https://www.freseniusmedicalcare.com

版塊Healthcare
行業Medical Care Facilities
全職員工117,128

高階主管

名稱頭銜支付行使價出生年份
Ms. Helen GizaChair of Management Board & CEO5.27M1968
Mr. Martin FischerCFO & Member of the Management Board949.23k1978
Dr. Franklin W. Maddux F.A.C.P.Global Chief Medical Officer & Member of Management Board2.97M1957
Dr. Katarzyna Mazur-Hofsab Ph.D.CEO of Care Enablement & Member of Management Board3.09M1963
Mr. Craig Cordola FACHE, M.B.A., M.H.A.CEO of Care Delivery & Member of Management Board1969
Dr. Dominik HegerExecutive VP and Head of Investor Relations, Strategic Development & Communications
Mr. Jorg HaringGlobal Head of Legal, Compliance & Human Resources and Labor Director
Mr. Joachim WeithSenior Vice President of Corporate Communications & Governmental Affairs
Dr. Gail-Suzanne BrownSenior Vice President of Research & Development
Mr. Glenn SlaterSenior Vice President of Manufacturing and Supply Chain Operations
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

公司管治

截至 2024年6月1日 止,Fresenius Medical Care AG 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中:8;董事會:6;股東權利:1;現金賠償:3。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。